Phase 2/3 of umbilical cord outer lining-derived stem cells
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Umbilical cord derived mesenchymal stem cell therapy-RESTEM (Primary)
- Indications Dermatomyositis; Polymyositis
- Focus Therapeutic Use
- 25 Nov 2024 New trial record
- 18 Nov 2024 According to a RESTEM media release, company plans to initiate this study in 1Q 2025.